Skip to main content
$36.27 $1.59 (4.6%)

04:00 PM EDT on 05/07/21

REGENXBIO (NASDAQ:RGNX)

CAPS Rating: 4 out of 5

Current Price $36.27 Mkt Cap $1.5B
Open $35.34 P/E Ratio 0.00
Prev. Close $36.27 Div. (Yield) $0.00 (0.0%)
Daily Range $34.55 - $36.47 Volume 580,420
52-Wk Range $25.93 - $50.26 Avg. Daily Vol. 345,982

Caps

How do you think NASDAQ:RGNX will perform against the market?

Add Stock to CAPS Watchlist

All Players

36 Outperform
1 Underperform
 

All-Star Players

14 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:RGNX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:RGNX VS S&P 500 (SPY)

NASDAQ:RGNX Summary

Fools bullish on NASDAQ:RGNX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about RGNX.

Recs

0
Member Avatar tking123 (66.06) Submitted: 1/8/2021 12:55:00 PM : Outperform Start Price: $47.21 NASDAQ:RGNX Score: -34.32

Small company targeting eye disease gene therapy. Its eye-disease treatment is being tested in people with wet age-related macular degeneration. This is a big market and the leaders are Roche and Regeneron Pharmaceuticals.....Keep an eye on this one.

Recs

0
Member Avatar findil (90.68) Submitted: 9/27/2018 12:08:01 PM : Outperform Start Price: $76.70 NASDAQ:RGNX Score: -97.46

Love the optionality of partners and internal pipeline combined with a differentiated competitive advantage.

Recs

0
Member Avatar TMFEBCapital (97.32) Submitted: 7/12/2018 12:41:22 PM : Outperform Start Price: $74.85 NASDAQ:RGNX Score: -102.96

Big risk, big reward. Data from phase 1 trials in wet AMD and HoFH are on tap later this year. Solid balance sheet helped by $100 million payment in June from Novartis tied to NVS acquisition of AveXis, which is developing AVXS-101, an SMA gene therapy using RGNX's viral vectors.

Leaderboard

Find the members with the highest scoring picks in RGNX.

Score Leader

otherAquanaut

otherAquanaut (99.68) Score: +172.80

The Score Leader is the player with the highest score across all their picks in RGNX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
otherAquanaut 99.68 3/30/2016 10/7/2020 Outperform 3M $9.61 +277.42% +104.61% +172.80 0 Comment
portefeuille 98.38 3/24/2016 Outperform 5Y $9.85 +268.22% +108.38% +159.84 0 Comment
portefeuille2 98.83 9/12/2016 Outperform 5Y $12.82 +182.92% +98.75% +84.17 0 Comment
clangmead 48.27 9/12/2016 Outperform 5Y $12.82 +182.92% +98.75% +84.17 1 Comment
efarev 64.46 5/23/2017 Outperform 5Y $18.60 +95.00% +75.86% +19.14 0 Comment
kkconway 99.01 4/26/2021 Outperform 5Y $35.53 +2.08% +1.06% +1.02 0 Comment
naughtyguy 32.79 5/7/2021 Underperform 5Y $35.34 +2.63% +0.53% -2.10 0 Comment
StockFlyer 43.35 9/21/2020 Outperform 5Y $29.83 +21.59% +29.60% -8.01 0 Comment
Stlongs 36.96 8/17/2020 Outperform 5Y $32.06 +13.13% +24.89% -11.76 0 Comment
TMFSaintCroix 99.70 1/22/2018 Outperform 5Y $27.15 +33.59% +49.79% -16.20 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for RGNX.